3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Breast
2
Tumor-Agnostic
1
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
CNS
1
Conditions
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Endometrial Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Interventions
Carboplatin
66
Paclitaxel
54
pembrolizumab
49
Cyclophosphamide
34
Cisplatin
28
Bevacizumab
26
Nivolumab
21
Gemcitabine
18
fludarabine
17
liposomal doxorubicin
15
Topotecan
15
aldesleukin
13
Filgrastim
12
olaparib
11
Interleukin-2
11
Docetaxel
11
Peripheral Blood Stem Cell Transplantation
10
durvalumab
9
Taxes
9
Specimen Handling
9
Oxaliplatin
8
fludarabine phosphate
7
epacadostat
7
Magnetic Resonance Spectroscopy
7
Ipilimumab
7
Injections
7
rucaparib
6
niraparib
6
lenvatinib
6
cemiplimab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Colony-Stimulating Factors
×
Gynecologic
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled